Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Short-term outcomes of olfaction in patients with eosinophilic chronic rhinosinusitis after endoscopic sinus surgery and an assessment of prognostic factors.

Akiyama K, Samukawa Y, Hoshikawa H.

Int Forum Allergy Rhinol. 2019 Nov 21. doi: 10.1002/alr.22491. [Epub ahead of print]

PMID:
31752045
2.

Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis.

Akiyama K, Makihara S, Uraguchi K, Samukawa Y, Oka A, Hoshikawa H.

Int Arch Allergy Immunol. 2019;179(2):81-88. doi: 10.1159/000496437. Epub 2019 Feb 22.

PMID:
30799396
3.

Glabridin inhibits dexamethasone-induced muscle atrophy.

Yoshioka Y, Kubota Y, Samukawa Y, Yamashita Y, Ashida H.

Arch Biochem Biophys. 2019 Mar 30;664:157-166. doi: 10.1016/j.abb.2019.02.006. Epub 2019 Feb 13.

PMID:
30771297
4.

A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells.

Kitakaze T, Makiyama A, Samukawa Y, Jiang S, Yamashita Y, Ashida H.

Arch Biochem Biophys. 2019 Mar 15;663:151-159. doi: 10.1016/j.abb.2019.01.012. Epub 2019 Jan 11.

PMID:
30641047
5.

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.

Shirai K, Fujita T, Tanaka M, Fujii Y, Shimomasuda M, Sakai S, Samukawa Y.

Adv Ther. 2019 Jan;36(1):86-100. doi: 10.1007/s12325-018-0835-5. Epub 2018 Dec 10.

6.

Assessment of Simultaneous Surgery for Odontogenic Sinusitis: Endoscopic Sinus Surgery With Endoscopic Apicoectomy.

Akiyama K, Nakai Y, Samukawa Y, Miyake M, Hoshikawa H.

J Craniofac Surg. 2019 Jan;30(1):239-243. doi: 10.1097/SCS.0000000000005134.

PMID:
30444772
7.

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.

Shirai K, Tanaka M, Fujita T, Fujii Y, Shimomasuda M, Sakai S, Samukawa Y.

Adv Ther. 2019 Jan;36(1):217-231. doi: 10.1007/s12325-018-0822-x. Epub 2018 Nov 1.

8.

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, Sakai S.

Clin Pharmacol Drug Dev. 2018 Nov;7(8):820-828. doi: 10.1002/cpdd.456. Epub 2018 Apr 25.

9.

Clinical effects of submucosal middle turbinectomy for eosinophilic chronic rhinosinusitis.

Akiyama K, Samukawa Y, Takahashi S, Ouchi Y, Hoshikawa H.

Auris Nasus Larynx. 2018 Aug;45(4):765-771. doi: 10.1016/j.anl.2017.11.013. Epub 2017 Nov 26.

PMID:
29239727
10.

Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.

Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, Sakai S, Kumagai Y.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):439-447. doi: 10.1002/cpdd.364. Epub 2017 Aug 7.

PMID:
28783873
11.
12.

SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications.

Kojima N, Samukawa Y, Takahashi T.

Nihon Yakurigaku Zasshi. 2016;148(5):253-258. doi: 10.1254/fpj.148.253. Japanese. No abstract available.

PMID:
27803438
13.

Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.

Miyata A, Hasegawa M, Hachiuma K, Mori H, Horiuchi N, Mizuno-Yasuhira A, Chino Y, Jingu S, Sakai S, Samukawa Y, Nakai Y, Yamaguchi JI.

Xenobiotica. 2017 Apr;47(4):332-345. doi: 10.1080/00498254.2016.1193263. Epub 2016 Jun 27.

PMID:
27347703
14.

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.

Samukawa Y, Omiya H, Watase H, Nozaki K, Sakai S, Nishimura R.

Adv Ther. 2016 Jul;33(7):1215-30. doi: 10.1007/s12325-016-0350-5. Epub 2016 Jun 2.

15.

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.

Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y.

Clin Ther. 2016 Apr;38(4):843-862.e9. doi: 10.1016/j.clinthera.2016.01.017. Epub 2016 Mar 25.

16.

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.

Jinnouchi H, Nozaki K, Watase H, Omiya H, Sakai S, Samukawa Y.

Adv Ther. 2016 Mar;33(3):460-79. doi: 10.1007/s12325-016-0291-z. Epub 2016 Feb 5.

17.

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y.

Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22.

18.

Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.

Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y.

Diabetes Obes Metab. 2016 Jul;18(7):702-6. doi: 10.1111/dom.12611. Epub 2016 Jan 15.

19.

Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis.

Yonezaki M, Akiyama K, Karaki M, Goto R, Inamoto R, Samukawa Y, Kobayashi R, Kobayashi E, Hoshikawa H.

Auris Nasus Larynx. 2016 Jun;43(3):292-7. doi: 10.1016/j.anl.2015.09.003. Epub 2015 Oct 21.

PMID:
26498699
20.

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.

Kumagai Y, Hasunuma T, Sakai S, Ochiai H, Samukawa Y.

PLoS One. 2015 Oct 7;10(10):e0139873. doi: 10.1371/journal.pone.0139873. eCollection 2015.

21.

Corrigendum.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2015 Dec;31(12):2345. doi: 10.1185/03007995.2015.1093404. Epub 2015 Sep 22. No abstract available.

PMID:
26393294
22.

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.

Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

J Diabetes Investig. 2015 Jul;6(4):443-53. doi: 10.1111/jdi.12316. Epub 2015 Jan 10.

23.

Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.

Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Adv Ther. 2015 May;32(5):404-17. doi: 10.1007/s12325-015-0209-1. Epub 2015 May 15.

24.

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Seino Y, Kaku K, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Endocr J. 2015;62(7):593-603. doi: 10.1507/endocrj.EJ15-0097. Epub 2015 May 12.

25.

Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.

Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, Ubukata M, Sakai S, Samukawa Y.

Diabetes Obes Metab. 2015 Aug;17(8):800-4. doi: 10.1111/dom.12481. Epub 2015 Jun 4.

26.

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.

Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Adv Ther. 2015 Apr;32(4):319-40. doi: 10.1007/s12325-015-0200-x. Epub 2015 Apr 9.

27.

Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.

Hoshikawa H, Mori T, Yamamoto Y, Kishino T, Fukumura T, Samukawa Y, Mori N, Nishiyama Y.

Clin Nucl Med. 2015 Jun;40(6):464-8. doi: 10.1097/RLU.0000000000000652.

PMID:
25546204
28.

Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers.

Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, Mori N, Nishiyama Y.

Ann Nucl Med. 2014 Dec;28(10):1020-6. doi: 10.1007/s12149-014-0902-1. Epub 2014 Sep 2.

PMID:
25179522
29.

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.

Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I.

Biopharm Drug Dispos. 2014 Oct;35(7):391-404. doi: 10.1002/bdd.1909. Epub 2014 Aug 6.

30.

A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.

Mizuno-Yasuhira A, Nakai Y, Gunji E, Uchida S, Takahashi T, Kinoshita K, Jingu S, Sakai S, Samukawa Y, Yamaguchi J.

Drug Metab Dispos. 2014 Sep;42(9):1456-65. doi: 10.1124/dmd.114.058305. Epub 2014 Jul 8.

PMID:
25005603
31.

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1245-55. doi: 10.1185/03007995.2014.912983. Epub 2014 Apr 29.

PMID:
24708292
32.

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1231-44. doi: 10.1185/03007995.2014.909390. Epub 2014 Apr 15. Erratum in: Curr Med Res Opin. 2015 Dec;31(12):2345.

PMID:
24673496
33.

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.

Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1219-30. doi: 10.1185/03007995.2014.901943. Epub 2014 Mar 19.

PMID:
24597840
34.

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y.

Adv Ther. 2014 Mar;31(3):345-61. doi: 10.1007/s12325-014-0102-3. Epub 2014 Feb 18.

35.

Blindness caused by septic superior ophthalmic vein thrombosis in a Lemierre Syndrome variant.

Akiyama K, Karaki M, Samukawa Y, Mori N.

Auris Nasus Larynx. 2013 Oct;40(5):493-6. doi: 10.1016/j.anl.2012.09.006. Epub 2012 Oct 22. Review.

PMID:
23084837

Supplemental Content

Loading ...
Support Center